Aspen has a strong global presence in both emerging and developed countries
with more than 60 established business operations in approximately 50 countries.

Aspen has a strong global presence in both emerging and developed countries
with more than 60 established business operations in approximately 50 countries.

ABOUT ASPEN

We have a proud heritage dating back more than 160 years and we are committed to sustaining life and promoting healthcare through increasing access to our high quality, affordable medicines and products.

With a market capitalisation of approximately US$10 billion, we are the largest pharmaceutical company listed on the JSE Limited (share code: APN) and we are ranked among the top 30 listed companies on this exchange.

SENS ANNOUNCEMENTS

INVESTOR CALENDAR

8 March 2018
Interim results announcement

9 March 2018
Interim results presentation in Cape Town

30 June 2018
Financial year end

13 September 2018
Year end results announcement, presentation and webcast at the JSE, Johannesburg. The webcast will be available from 08:30

Click here for the 2018 results presentation

November 2018
Annual financial statements for 2018 year end published

6 December 2018
Annual General Meeting

LATEST RESULTS

Aspen 2018 Integrated Report

Aspen 2018 Annual Financial Statements

Aspen 2018 Year End Results for the year ended 30 June 2018

Aspen 2018 Year End Results short form announcement

Aspen 2018 Year End Results presentation

Aspen 2018 Year End Results webcast

Regional
Overviews

DEVELOPED EUROPE

SUB-SAHARAN AFRICA

AUSTRALASIA

LATIN AMERICA

DEVELOPING EUROPE & CIS

China

Japan

Other Asia

Middle East and North Africa

USA & Canada

DEVELOPED EUROPE

Our Developed Europe business is made up of operations in Europe’s major developed countries. The Anaesthetics and Thrombosis portfolios are the leading therapeutic focused brands in Developed Europe. The API site at Oss, supported by its satellite operation at Sioux City, supplies APIs worldwide. The Notre Dame de Bondeville and Bad Oldesloe sites are strategically important manufacturers for the Group.

Key countries
France
Germany
Italy
The Netherlands
United Kingdom
Products launched in 2018
Nil
(2017: nil)

IMS value of pipeline as at 30 June 2018 anticipated to be launched in:
0 – 2 years
USDnil


3 – 5 years
USDnil

SUB-SAHARAN AFRICA

The SSA business provides a diverse basket of branded, generic, OTC and consumer health products which are supplied to both the private and public sectors primarily in South Africa. Our presence outside of South Africa is mainly in Namibia, Botswana, Tanzania, Kenya, Nigeria, Ghana and Uganda.

Key countries
Botswana
Kenya
Namibia
South Africa
Tanzania
Products launched in 2018
10
(2017: 11)

IMS* value of pipeline as at 30 June 2018 anticipated to be launched in:
0 – 2 years
USD119 million


3 – 5 years
USD250 million

*South Africa only, rest of SSA not covered by IMS.

Australasia

 

We supply a diversified portfolio of branded prescription, OTC, consumer and infant nutritional products into Australia and New Zealand. We are one of the largest manufacturers in Australia and our manufacturing site in Melbourne produces certain tablets, liquids and semisolids.

Key countries
Australia
New Zealand
Products launched in 2018
3
(2017: 4)
 

IMS value of pipeline as at 30 June 2018 anticipated to be launched in:
0 – 2 years
USD113 million


3 – 5 years
USD11 million

 

Latin America

 

We entered the Latin American market in 2008 and initially established a presence in Brazil, Mexico and Venezuela. We have expanded our coverage in this region and now also have a presence in Colombia, Chile, Ecuador, Costa Rica, Peru and Argentina and offer a comprehensive product range that encompasses branded prescription and OTC products as well as infant nutritionals. Our Vallejo site in Mexico has the capability to manufacture infant nutritionals as well as pharmaceutical solids, semisolids and liquids.

Key countries
Brazil
Chile
Colombia
Ecuador
Mexico
Products launched in 2018
11
(2017: 26)
 

IMS value of pipeline as at 30 June 2018 anticipated to be launched in:
0 – 2 years
USD424 million


3 – 5 years
USD298 million

 

Developing Europe & CIS

The main revenue contributor to our Developing Europe & CIS business is the Thrombosis portfolio. The Anaesthetics portfolio is anticipated to become a significant contributor in this region.

Key countries
Czech Republic
Poland
Romania
Russia
Slovakia
Products launched in 2018
Nil
(2017: 1)

IMS value of pipeline as at 30 June 2018 anticipated to be launched in:
0 – 2 years
USD4 million


3 – 5 years
USDnil

China

 

Aspen China is set to become a significant contributor to the Group performance with a product range comprising the recently acquired Thrombosis and Anaesthetic Brands as well as some smaller global brands.

 
Products launched in 2018

Nil
(2017: nil)
 

IMS value of pipeline as at 30 June 2018 anticipated to be launched in:
0 – 2 years
USDnil


3 – 5 years
USD13 million

 

Japan

 

Aspen Japan operates according to a flexible business model and employs innovative marketing activities to promote leading international pharmaceutical originator brands and authorised generics in Japan.

 
Products launched in 2018

9
(2017: 9)
 

IMS value of pipeline as at 30 June 2018 anticipated to be launched in:
0 – 2 years
USDnil


3 – 5 years
USDnil

 

Other Asia

Other Asia comprises all Asian territories excluding China and Japan. Anaesthetics make up 46% of revenue in these countries, followed by several products in the Regional Brands category. We have active trading subsidiaries in the Philippines, Taiwan and Malaysia.

Key countries and territories
Hong Kong
Philippines
Singapore
Taiwan
Products launched in 2018
3
(2017: nil)

IMS value of pipeline as at 30 June 2018 anticipated to be launched in:
0 – 2 years
USD45 million


3 – 5 years
USD1 million

Middle East and North Africa

We supply globally branded pharmaceutical products as well as local brands into multiple territories within Middle East and North Africa (“MENA”). Egypt, Algeria and Saudi Arabia combined contributed approximately 50% to total sales in MENA for the 2018 financial year.

Key countries
Algeria
Egypt
Morocco
Saudi Arabia
United Arab Emirates
Products launched in 2018
8
(2017: 2)

IMS value of pipeline as at 30 June 2018 anticipated to be launched in:
0 – 2 years
USD160 million


3 – 5 years
USD3 million

USA & Canada

Aspen Pharmacare Canada was founded in 2014 to support our products distributed in this region. The development of our complex API capabilities into niche FDF offerings represents an opportunity for future product launches in the United States. Our satellite API facility in Sioux City supports the Oss site in supplying APIs worldwide.

Key countries
Canada
USA
Products launched in 2018
1
(2017: 3)

IMS value of pipeline as at 30 June 2018 anticipated to be launched in:
0 – 2 years
USD449 million


3 – 5 years
USD1 522 million